USPTO Patents Application 09927422

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO

\ INFORMATION DISCLOSURE
w| STATEMENT BY APPLICANT

(Use as many she ets as necess ary)

Complete if Known

Application Number

09/927,422

Filing Date

August 10, 2001

First Named Inventor

Gary VAN NEST

Art Unit

1645

Examiner Name

N. Minnifield

Sheet | 1 | of

2

Attorney Docket Number

377882001420

U.S. PATENT DOCUMENTS

Examiner
Initiate*

Cite
No. 1

Document Number

Publication Date
MM-DD-YYYY

Name of Patentee or
Applicant of Cited Document

Pages, Columns, Lines, Where
Relevant Passages or Relevant
Figures Appear

Number-Kind Code 2 (if known)

1.

US-2002/0055477-A1

05-09-2002

Nest et al.

2.

US-2003/0059773-A1

03-27-2003

Van Nestet al.

3.

US-5.629.158-A

05-13-1997

Uhlen

4.

US-5.770.434-A

06-23-1998

Huse

5.

US-5.824.812-A

10-20-1998

Nantz et al.

6.

US-6.352.975-B1

03-05-2002

Schreiner et al.

7.

US-6.355.267-B1

03-12-2002

Collins

8.

US-6.465.188-B1

10-15-2002

Gold et al.

9.

US-6,559,129-B1

05-06-2003

Kasid et al.

FOREIGN PATENT DOCUMENTS

Examiner
Initials*

Cite
No. 1

Foreign Patent Document

Publication
Date
MM-DD-YYYY

Name of Patentee or

Pages, Columns, Lines,
Where Relevant Passages
or Relevant Figures Appear

Country Code'-Numbei^-Kind Code* (if known)

Applicant of Cited Document

T 3

10.

WO-03/015816-A1

02-27-2003

Dynavax Technologies
Corporation

•EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
considered Include copy of this form with next communication to applicant. ' Applicant's unique citation designation number (optional). See Kinds Codes of
USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For
Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by
the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language
Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials'

Cite
No. 1

Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,
magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city

and/or country where published.

T 2

11.

Agrawal, S. et al. (Febraury 2000). "Antisense Therapeutics: is it as Simple as Complementary
Base Recognition?," Molecular Med. Today 6:72-81.

12.

Busquets, MA et al. (November 2003). "Peptides and Liposomes: From Biophysical to
Immunogenic Studies/'Cu/renf Drug Targets 4(8):633-642.

13.

Crnn K p ST (1QQR) "Ra^in Principles of Antisense Therapeutics." Chapter 1 In Antisense
Research and ADDlication, Crooke, ST. ed., Springer-Verlag: Berlin, Germany, pp. 1-50.

14.

Du Bois, R.M. (October 21, 1999). "Interferon Gamma-1b for the Treatment of Idiopathic
Pulmonary Fibrosis," New England Journal of Medicine 341(17):1302-1304.

15.

Fearon, K. et al. (2003). "A Minimal Human Immunostimulatory CpG Motif That Potently
Induces IFN-v and IFN-a Production," Eur. J. Immunol. 33:2114-2122.

16,

Fix, M. et al. (2002). "The Fluorosome"" Technique for Investigating Membrane On- and Off-
Loadinq of Druqs by 3-CD and Sonicated SUV," FEBS Letters 516:109-1 12.

17.

International Search Report mailed on February 11, 2002 for PCT Application No,
PCT/US01/07848 filed March 12, 2001, three pages.

18.

International Search Report mailed on August 27, 2002 for PCT Application No.
PCT/US01/25364 filed Auqust 13, 2001, four pages.

19,

International Search Report mailed on February 11, 2002 for PCT Application No.
PCT/US01/07843 filed March 12, 2001, three pages.

20.

Li, Q.T. et al. (1993). "Effect of Cholesteryl Ester on the Distribution of Fluorescent Cholesterol
Analogues in Triacylglycerol-rich Emulsions," Biochimica et Biophysica Acta 1 166(2/3): 145-

Examiner

Date

Signature

Considered

pa- 1058859

ALTERNATIVE TO PTO/SB/08a/b (07-05)

SEP 01.

Substitute for form 1449/PTO

\ INFORMATION DISCLOSURE
tj STATEMENT BY APPLICANT

(Use as many sheets as necess ary)

Complete if Known

Application Number

09/927,422

Filing Date

August 10, 2001

First Named Inventor

Gary VAN NEST

Art Unit

1645

Examiner Name

N. Minnifield

Sheet | 2

of

2

Attorney Docket Number

377882001420

153.

21.

Peracchi, A. (2004). "Prospects for Antiviral Ribozymes and Deoxyribozymes," Rev. Med.
Virol. 14:47-64.

22.

Stayton, P.S. et al. (2000). "Molecular Engineering of Proteins and Polymers for Targeting and
Intracellular Delivery of Therapeutics," J. Controlled Release 65:203-220.

23.

Van Uden, J. et al. (November 1999). "Immunostimulatory DNA and Applications to Allergic
Disease/' Journal of Allergy and Clinical Immunology 104(5):902-910.

•EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Examiner

Date

Signature

Considered

pa- 1058859